ADC Digest - August 2020

ADC Digest - August 2020

Antibody–drug conjugates (ADCs)

ADC ‘s are the next generation “targetted” missiles being built in different shapes and forms to attack the enemy in a multitude of ways. What is an ADC – its is a monoclonal antibody tethered to a payload via a chemical linker. They lack the complexity of CAR-Ts, but have their own “improvement” areas. It will be a new weapon in our armamentarium. In the span of 2 weeks we saw both GlaxoSmithKline and AstraZeneca moving ahead with their ADC programs. Read more, tile wise below

Regulatory
AbbVie’s Temab-A receives FDA Breakthrough Therapy Designations for CRC and NSCLC
Regulatory
[²¹²Pb]PSV359 receives FDA Fast Track Designation for FAP-positive solitary fibrous tumors
Regulatory
Crescent Biopharma receives FDA IND clearance for CR-002 in Solid tumors
Regulatory
Perioperative Imfinzi plus Enfortumab vedotin received U.S. FDA Priority Review for MIBC
Regulatory
BL-M05D1 received BTD in China for previously treated advanced Gastric/GEJ cancer
Regulatory
Ifinatamab deruxtecan BLA for previously treated extensive-stage SCLC was voluntarily withdrawn in the U.S.